CD20 Antibody (Hu202) [Unconjugated]

HEK293 cells transfected with Human CD20-eGFP (A) vs irrelevant-GFP (B) were stained with Human Anti-Human CD20 Monoclonal Antibody (Catalog # MAB11595) followed by Allophycocyanin-conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow
• Clone: Hu202
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated

CD20 Antibody (Hu202) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody For Research Use Only
• Immunogen: Human CD20
• Specificity: Stains hCD20-eGFP transfected HEK293 cells in flow cytometry.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD20 Antibody (Hu202) [Unconjugated]

• B1
• B-lymphocyte antigen CD20
• B-lymphocyte cell-surface antigen B1
• B-lymphocyte surface antigen B1
• Bp35
• Bp35MGC3969
• CD20 antigen
• CD20 receptor
• CD20
• CD20S7
• CVID5
• LEU-16
• Leukocyte surface antigen Leu-16
• Ly-44
• Membrane-spanning 4-domains subfamily A member 1
• membrane-spanning 4-domains, subfamily A, member 1
• MS4A1
• MS4A2
• S7

Background

Ocrelizumab is an anti-human CD20 antibody used for the treatment of advanced or relapsing multiple sclerosis.  It is a humanized recombinant anti human CD20 antibody, and is used to specifically deplete B-cells.  A proposed pharmacological mechanism of action is that the antibody most likely binds to the B-cell surface CD20 resulting in antibody-dependent cellular cytotoxicity and complement-mediated cell lysis, but does not impact B-cell reconstitution and preexisting humoral immunity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.